Financials
Financial year 2025
LA BRABANÇONNE PHARMA from Schaarbeek, company number BE1025693638, closed financial year 2025 with a result of € -39,825 after tax. For that financial year LA BRABANÇONNE PHARMA recorded a gross margin of € 75,175 and equity of € 60,175. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
€ 60,175
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -39,825
Profit after tax over the fiscal year.
€ 105,922
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -39,825.
People and assets in 2025
3.1
Average over the fiscal year, from the social balance sheet.
€ 47,659
€ 15,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 121,875
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 922,842
€ 67,455 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.
€ 107,431
Supplier invoices still open on the last day of the fiscal year.
€ 17,348
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
What happened to LA BRABANÇONNE PHARMA?
What happened at LA BRABANÇONNE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 39,825. Source: NBB ↗
- New establishment in Schaarbeek. KBO
- Start of the company according to the CBE. KBO
In short
On average € 24,200 of value added per employee in 2025.
A new publication or filing at LA BRABANÇONNE PHARMA? We notify you, reason included.
Follow LA BRABANÇONNE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NOVATRIX PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
LA BRABANÇONNE PHARMABehind LA BRABANÇONNE PHARMA is NOVATRIX PHARMA SA. The shares are held by NOVATRIX PHARMA (100%).
Directors
According to the 2025 annual accounts
Director · represented by HOUCH Oussama
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Brabançonnelaan 139
1030 Schaarbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1025.693.638
- VAT number
- BE 1025.693.638
- Registered office
- Brabançonnelaan 139, 1030 Schaarbeek
- Names & denominations
- LA BRABANÇONNE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 July 2025
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Detailhandel in farmaceutische producten